All eight patients with crizotinib-naive ALK+ NSCLC had confirmed objective responses (confirmed ORR: 100% [95% CI: 63–100]; three patients had CRs and five patients had PRs), with median duration of response of 32.4 months (95% CI: 5.6–60.3). This evidence concerns the gene ALK and non-small cell lung carcinoma.